Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GW Pharmaceuticals plc stock logo
GWPH
GW Pharmaceuticals
$218.96
$218.59
$87.07
$219.57
$6.86B2.15899,771 shsN/A
Beigene, Ltd. stock logo
ONC
Beigene
$225.77
+2.6%
$243.76
$141.31
$287.88
$22.36B0.35479,783 shs454,203 shs
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
$33.12
+2.6%
$32.36
$24.05
$34.20
$19.09B0.493.32 million shs3.33 million shs
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$16.83
-0.4%
$15.34
$12.47
$22.80
$19.08B0.629.98 million shs9.48 million shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GW Pharmaceuticals plc stock logo
GWPH
GW Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Beigene, Ltd. stock logo
ONC
Beigene
+2.65%-4.89%-5.47%-2.20%+22,576,999,900.00%
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
+2.57%+0.11%+2.06%+2.35%+17.41%
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
+0.84%-7.17%+23.89%+3.66%+0.30%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
GW Pharmaceuticals plc stock logo
GWPH
GW Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Beigene, Ltd. stock logo
ONC
Beigene
3.0864 of 5 stars
4.50.00.00.02.31.70.6
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
4.4987 of 5 stars
3.51.03.33.72.91.71.3
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
3.5096 of 5 stars
3.65.00.80.04.00.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
GW Pharmaceuticals plc stock logo
GWPH
GW Pharmaceuticals
0.00
N/AN/AN/A
Beigene, Ltd. stock logo
ONC
Beigene
3.00
Buy$319.0041.29% Upside
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
3.00
Buy$42.5028.32% Upside
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
3.13
Buy$24.4345.15% Upside

Current Analyst Ratings Breakdown

Latest GWPH, ONC, TEVA, and RPRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/12/2025
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Overweight$21.00 ➝ $23.00
5/8/2025
Beigene, Ltd. stock logo
ONC
Beigene
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$312.00 ➝ $311.00
5/8/2025
Beigene, Ltd. stock logo
ONC
Beigene
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$348.00 ➝ $350.00
5/8/2025
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$20.00 ➝ $22.00
4/28/2025
Beigene, Ltd. stock logo
ONC
Beigene
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$312.00 ➝ $312.00
4/28/2025
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/24/2025
Beigene, Ltd. stock logo
ONC
Beigene
TD Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$334.00 ➝ $334.00
4/21/2025
Beigene, Ltd. stock logo
ONC
Beigene
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$311.00 ➝ $317.00
4/16/2025
Beigene, Ltd. stock logo
ONC
Beigene
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
4/10/2025
Beigene, Ltd. stock logo
ONC
Beigene
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$348.00 ➝ $348.00
4/7/2025
Beigene, Ltd. stock logo
ONC
Beigene
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$312.00
(Data available from 5/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
GW Pharmaceuticals plc stock logo
GWPH
GW Pharmaceuticals
$311.33M22.05$0.01 per share18,588.22$23.48 per share9.33
Beigene, Ltd. stock logo
ONC
Beigene
$4.18B5.36N/AN/A$37.10 per share6.09
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
$2.26B8.43$4.17 per share7.94$17.94 per share1.85
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$16.62B1.15$3.33 per share5.05$4.75 per share3.54
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
GW Pharmaceuticals plc stock logo
GWPH
GW Pharmaceuticals
-$9.02M-$0.24N/A608.22N/A-11.05%-7.46%-6.13%N/A
Beigene, Ltd. stock logo
ONC
Beigene
-$881.71M-$3.72N/A317.997.73-25.94%-25.12%-14.95%N/A
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
$858.98M$1.8522.846.812.3137.94%24.40%14.01%N/A
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
-$1.64B-$1.15N/A6.401.44-9.91%42.46%6.65%7/30/2025 (Estimated)

Latest GWPH, ONC, TEVA, and RPRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
$0.99$1.06+$0.07$0.41$724.69 million$839.00 million
5/7/2025Q1 2025
Beigene, Ltd. stock logo
ONC
Beigene
-$0.71$1.22+$1.93$0.01$1.12 billion$1.12 billion
5/7/2025Q1 2025
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$0.47$0.52+$0.05$0.18$3.99 billion$3.89 billion
2/27/2025Q4 2024
Beigene, Ltd. stock logo
ONC
Beigene
-$0.88-$1.43-$0.55-$1.43$1.09 billion$1.13 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
GW Pharmaceuticals plc stock logo
GWPH
GW Pharmaceuticals
N/AN/AN/AN/AN/A
Beigene, Ltd. stock logo
ONC
Beigene
N/AN/AN/AN/AN/A
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
$0.882.66%+7.30%47.57%5 Years
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$1.016.01%N/AN/A N/A

Latest GWPH, ONC, TEVA, and RPRX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/21/2025
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
quarterly$0.222.7%5/16/20255/16/20256/10/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
GW Pharmaceuticals plc stock logo
GWPH
GW Pharmaceuticals
0.01
5.13
4.31
Beigene, Ltd. stock logo
ONC
Beigene
0.05
1.93
1.72
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
0.64
1.44
1.44
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
2.97
0.98
0.75

Institutional Ownership

CompanyInstitutional Ownership
GW Pharmaceuticals plc stock logo
GWPH
GW Pharmaceuticals
81.00%
Beigene, Ltd. stock logo
ONC
Beigene
48.55%
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
54.35%
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
54.05%

Insider Ownership

CompanyInsider Ownership
GW Pharmaceuticals plc stock logo
GWPH
GW Pharmaceuticals
3.10%
Beigene, Ltd. stock logo
ONC
Beigene
6.62%
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
18.90%
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
0.49%
CompanyEmployeesShares OutstandingFree FloatOptionable
GW Pharmaceuticals plc stock logo
GWPH
GW Pharmaceuticals
1,16131.35 millionN/AOptionable
Beigene, Ltd. stock logo
ONC
Beigene
9,00099.05 million90.59 millionN/A
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
80576.45 million477.83 millionOptionable
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
36,8001.13 billion1.13 billionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
GW Pharmaceuticals stock logo

GW Pharmaceuticals NASDAQ:GWPH

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of schizophrenia, autism spectrum disorder, neuropsychiatric symptom, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.

Beigene stock logo

Beigene NASDAQ:ONC

$225.77 +5.82 (+2.65%)
As of 05/15/2025 04:00 PM Eastern

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

Royalty Pharma stock logo

Royalty Pharma NASDAQ:RPRX

$33.12 +0.83 (+2.57%)
As of 05/15/2025 04:00 PM Eastern

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Teva Pharmaceutical Industries stock logo

Teva Pharmaceutical Industries NYSE:TEVA

$16.83 -0.06 (-0.36%)
As of 05/15/2025 03:53 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.